1 described the GITMO experience with rituximab as therapy for chronic graft-versus-host disease (cGVHD). In their series, an encouraging overall response rate of 65% was observed, particularly among patients with cutaneous cGVHD. One patient with cGVHD manifesting as a pure red cell aplasia (PRCA) failed to demonstrate response. Only one other report regarding the efficacy of rituximab for cGVHD manifesting as PRCA has been published to date; 2 here, we report a patient with PRCA as a manifestation of cGVHD who was successfully treated with single-agent rituximab.
A 44-year-old woman with primary, refractory stage IVB diffuse large B-cell lymphoma received myeloablative chemotherapy with busulfan and cyclophosphamide followed by a PBSC graft from a sex-mismatched, ABOmismatched (O þ patient/A þ donor) volunteer unrelated donor. Patient and donor were both CMV negative. On day þ 351, relapsed lymphoma was documented. After salvage chemotherapy, on day þ 524, she received a donor lymphocyte infusion. Since then, she has had no recurrent lymphoma or cGVHD, and is off all immunosuppression, with a Karnofsky performance status of 100%.
On day þ 1296 following her donor lymphocyte infusion, she complained of mild fatigue. Her hemoglobin was found to be abnormally low at 10.3 g per 100 ml (normal range 11.7-15.5 g per 100 ml) for the first time since her donor lymphocyte infusion. B12, folate and iron studies were normal and she had no evidence of relapsed lymphoma, hemolysis or blood loss. Her absolute reticulocyte count, however, was 0.0071 M/ml (normal range 0.024-0.084 M/ml). Her reticulocyte count was 0.2% (normal 0.5-1.5%). As shown in Figure 1 , her hemoglobin progressively declined to the point of requiring transfusion support. A bone marrow aspirate and biopsy revealed marked erythroid hypoplasia; the myeloid/erythroid ratio was 19:1. Small non-clonal, CD3-positive, CD5-positive lymphoid aggregates comprising o5% of the total marrow cellularity were observed. Her blood type was A þ (donor) and a 100% donor chimerism was found. A comprehensive evaluation for alternative etiologies for her PRCA was negative, including serologic assessment for Parvovirus B19, adenovirus, EBV, CMV, human herpes virus-6, HIV and hepatitis viruses. The patient received 375 mg/m 2 of intravenous rituximab weekly for 4 weeks. By week 4 of rituximab, her absolute reticulocyte count improved, her reticulocyte count had risen to the upper limit of the normal range and her hemoglobin had begun to rise. Now, nearly 5 months since onset, her hemoglobin has remained normal, and she remains without evidence of recurrent anemia or other manifestations of cGHVD.
PRCA following allogeneic stem cell transplantation can occur due to a number of reasons. Competing alternative diagnoses need to be excluded, including viral infection as well as anti-donor isohemagglutinin production by the recipient. 3 In the latter case, onset of cGVHD, in fact, was shown to resolve PRCA. Nonetheless, PRCA can occur as a manifestation of cGVHD specifically. 1, 4 Furthermore, A/O donor/recipientmismatch has been associated with a particular increase in the risk of development of PRCA post PBSCT. 5 A growing body of literature supports a role for rituximab as a therapy for cGVHD. [6] [7] [8] In most of these cases, mucocutaneous and musculoskeletal manifestations are most likely to respond. However, only two reports have included patients treated with rituximab for cGVHD manifesting as PRCA and have been associated with conflicting results. 1, 3 The mechanism of action is still under investigation; however, the successful use of rituximab in autoimmune conditions that clinically resemble cGVHD implies a potentially critical role for B cells and humoral immunity in cGVHD pathogenesis and potentiation. 9 Potential explanations include dysfunctional antibody production with autoimmune specificity as well as via facilitation of antibody-dependent cellular cytotoxicity and through antigen presentation to T cells. 10 The latter could potentially explain the small population of T cells observed in the patient's bone marrow, for example.
Our case adds to the growing experience with rituximab as a potential therapy for cGVHD, in particular in patients with PRCA. Clearly, more understanding is needed regarding the molecular mechanism of action and further clinical trials are warranted. cGVHD affects 70% or more long-term survivors of allogeneic stem cell transplantation and is a principal cause of significant morbidity and mortality. 11 Rituximab may be promising for such patients, particularly for those with steroid-refractory disease.
